How to Induce Arrhythmias with Dopamine

  • Shemaila Saleem


Dopamine is one of the most important neurotransmitters in the brain. It is a catecholamine derived from tyrosine and is the precursor of both noradrenaline and adrenaline. Dopamine is a monoamine with positive inotropic activity. It binds to both α-1 and beta-1 adrenergic receptors. It increases the cardiac output by increasing the heart rate and contractility mediated through myocardial β -1 adrenergic receptors. Stimulation of α-1 adrenergic receptors on vascular smooth muscle leads to vasoconstriction and results in increased systemic vascular resistance. Dopaminergic receptors from the renal vasculature are also stimulated by dopamine which leads to dilation of renal blood vessels and increases glomerular filtration rate, renal blood flow, sodium excretion, and urine outputGenerally, dopamine receptors are activated by low doses of dopamine (0.5–2.0 μg/kg/min), which causes a decrease in peripheral vascular resistance and left ventricular afterload. With the increase in dose (2–4 μg/kg/min), there was noted activation of β 1-adrenoceptors which, in turn, leads to increase in the cardiac output. A further increase in the dose (5 μg/kg/min) stimulates α-adrenoceptors resulting in vasoconstriction and amplified peripheral vascular resistance.


  1. 1.
    McGrath BP, Wang XQ. Dopamine: clinical applications iii. Cardiovascular. Aust Prescr. 1994;17:44–5.CrossRefGoogle Scholar
  2. 2.
    Wick M. Therapeutic effect of dopamine infusion on human malignant melanoma. Cancer Treat Rep. 1982;66:1657–9.PubMedGoogle Scholar
  3. 3.
    Shahar E, Lotan D, Barzilay Z. Dopamine-induced paroxysmal supraventricular tachycardia in an infant. Clin Pediatr. 1981;20:541–3.CrossRefGoogle Scholar
  4. 4.
    Kitamura T, Ohno N, Bougaki M, Saito Y, Orii R, Yamada Y. Second-degree atrioventricular block (Mobitz type II) probably exaggerated by dopamine during anesthetic management for a patient with ochronosis: a case report. Masui. 2008;57:1513–6.PubMedGoogle Scholar
  5. 5.
    Ozaki T, Uematsu T, Nagashima S, Nishimoto M, Nakashima M. Effects of DPI 201-106, a novel cardiotonic agent, on hemodynamics, cardiac electrophysiology and arrhythmias induced by programmed ventricular stimulation in dogs with subacute myocardial infarction: a comparative study with dobutamine. Naunyn Schmiedebergs Arch Pharmacol. 1991;344:478–87.CrossRefGoogle Scholar
  6. 6.
    Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis. 1995;38:167–80.CrossRefGoogle Scholar
  7. 7.
    Gelfman DM, Ornato JP, Gonzalez ER. Dopamine- induced increase in atrioventricular conduction in atrial fibrillation-flutter. Clin Cardiol. 1987;10:671–3.CrossRefGoogle Scholar
  8. 8.
    Day M, Roach A. Cardiovascular effects of dopamine after central administration into conscious cats. Br J Pharmacol. 1976;58:505–15.CrossRefGoogle Scholar
  9. 9.
    Ziegler M, Kennedy B, Holland O, Murphy D, Lake C. The effects of dopamine agonists on human cardiovascular and sympathetic nervous systems. Int J Clin Pharmacol Ther Toxicol. 1985;23:175–9.PubMedGoogle Scholar
  10. 10.
    Harris W, Van Petten G. The effects of dopamine on blood pressure and heart rate of the unanesthetized fetal lamb. Am J Obstet Gynecol. 1978;130:211–5.CrossRefGoogle Scholar
  11. 11.
    McDonald RH, Goldberg LI. Analysis of the cardiovascular effects of dopamine in the dog. J Pharmacol Exp Ther. 1963;140:60–6.Google Scholar
  12. 12.
    Gilbert J, Lange G, Polevoy I, Brooks CM. Effects of vasoconstrictor agents on cardiac irritability. J Pharmacol Exp Ther. 1958;123:9–15.PubMedGoogle Scholar
  13. 13.
    Alousi A. Cardiovascular effects of dopamine in the normal and failing heart of experimental animals. Recent Adv Stud Cardiac Struct Metab. 1975;6:291–300.PubMedGoogle Scholar
  14. 14.
    Holmes JC, Fowler NO. Direct cardiac effects of dopamine. Circ Res. 1962;10:68–72.CrossRefGoogle Scholar
  15. 15.
    Tisdale JE, Patel RV, Webb CR, Borzak S, Zarowitz BJ. Proarrhythmic effects of intravenous vasopressors. Ann Pharmacother. 1995;29:269–81.CrossRefGoogle Scholar
  16. 16.
    European Resuscitation Council. Part 6: advanced cardiovascular life support. Section 6: pharmacology II: agents to optimize cardiac output and blood pressure. European Resuscitation Council. Resuscitation. 2000;46:169–84.CrossRefGoogle Scholar
  17. 17.
    Imanaga I, Kaneda T, Miyakawa N. Comparison of the effects of dobutamine with dopamine and halothane anesthetized dogs. American journal of isoproterenol on inotropism and chronotropism in the mammalian heart (author’s transl). Nihon Yakurigaku Zasshi. 1979;75(2):147–57.CrossRefGoogle Scholar
  18. 18.
    Bischoff K, Hager W, Bödeker K. Electrophysiologic effects of dopamine on the cardiac conduction system (author’s transl). Z Kardiol. 1981;70(9):643–51.PubMedGoogle Scholar
  19. 19.
    Stetson JB, Reading GP. Avoidance of vascular complications associated with the use of dopamine. Can Anaesth Soc J. 1977;24(6):727–33.CrossRefGoogle Scholar
  20. 20.
    Argalious M, Motta P, Khandwala F, Samuel S, Koch CG, Gillinov AM, et al. “Renal dose” dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery. Crit Care Med. 2005;33(6):1327–32.CrossRefGoogle Scholar
  21. 21.
    Sampson KJ, Terrenoire C, Cervantes DO, Kaba RA, Peters NS, Kass RS. Adrenergic regulation of a key cardiac potassium channel can contribute to atrial fibrillation: evidence from an IKs transgenic mouse. J Physiol. 2008;586(2):627–37.CrossRefGoogle Scholar
  22. 22.
    Patterson E, Yu X, Huang S, Garrett M, Kem DC. Suppression of autonomic-mediated triggered firing in pulmonary vein preparations, 24 hours postcoronary artery ligation in dogs. J Cardiovasc Electrophysiol. 2006;17(7):763–70.CrossRefGoogle Scholar
  23. 23.
    Bednarski RM, Muir W. Arrhythmogenicity of dopamine, dobutamine, and epinephrine in thiamylal-halothane anesthetized dogs. Am J Vet Res. 1983;44(12):2341–3.PubMedGoogle Scholar
  24. 24.
    Tsompanidou PP, Kazakos GM, Anagnostou TL. Dopamine-induced bradycardia in two dogs under isoflurane anaesthesia. J Small Anim Pract. 2013;54(12):672–4.CrossRefGoogle Scholar
  25. 25.
    Perez-Olea J, Quevedo M, Silva R. Enhancement of blood pressure response to dopamine by angiotensin II. Hypertension. 1981;3(6 Pt 2):II-138–41.Google Scholar
  26. 26.
    Roquebert J, Moran A, Demichel P, Sauvage M-F. Pharmacological characterization of dopamine receptors in parasympathetic innervation of rat heart. Eur J Pharmacol. 1991;200(1):59–63.CrossRefGoogle Scholar
  27. 27.
    Orth OS, Stutzman JW, MEEK WJ. Relationship of chemical structure of sympathomimetic amines to ventricular tachycardia during cyclopropane anesthesia. J Pharmacol Exp Ther. 1944;81(2):197–202.Google Scholar
  28. 28.
    Loeb HS, Winslow EB, Rahimtoola SH, Rosen KM, Gunnar RM. Acute hemodynamic effects of dopamine in patients with shock. Circulation. 1971;44(2):163–73.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Shemaila Saleem
    • 1
  1. 1.Al-Farabi Centre, Federal Medical and Dental CollegeIslamabadPakistan

Personalised recommendations